Country for PR: United States
Contributor: PR Newswire New York
Tuesday, December 08 2020 - 01:49
PostEra enters a multi-year strategic partnership with Pfizer Inc. to advance machine learning for Drug Discovery
SAN FRANCISCO, Dec. 8, 2020 /PRNewswire-AsiaNet/ --

PostEra ( 
), a biotechnology company specializing in machine learning solutions for 
preclinical drug discovery, today announced a strategic partnership with Pfizer 
Inc. (NYSE: PFE) with the goal of accelerating small molecule drug discovery by 
developing a platform technology based on generative chemistry.

PostEra's machine learning technology is intended to accelerate the drug 
discovery process by designing novel molecular structures with optimised 
potency and drug-like properties. PostEra's approaches take chemical synthesis 
into account, as well as incorporate design hypotheses of medicinal chemists.

Through the collaboration, the companies will leverage Pfizer's extensive data 
and expertise with PostEra's technology capabilities to advance the science of 
generative chemistry to produce state-of-the-art, scalable models that could 
potentially be deployed across in-house, preclinical drug discovery efforts.

PostEra will receive an upfront payment and is eligible to receive additional 
payments as the project progresses. PostEra will also retain ownership rights 
to all algorithms developed during the collaboration.

"PostEra is delighted to be working with Pfizer to solve some of the key pain 
points in preclinical drug discovery," said Aaron Morris, CEO of PostEra. "As a 
team we are proud to be entering this collaboration and will be leveraging 
PostEra's many advances in machine learning to help Pfizer accelerate progress 
toward novel therapeutics."

"We believe that our investments in machine learning technologies could 
potentially help us expedite preclinical drug discovery. PostEra's technology 
complements this effort, and we look forward to seeing the results of the 
collaboration," said Charlotte Allerton, Head of Medicine Design, Pfizer.

About PostEra
PostEra was founded in 2019 and its technology is built on pioneering academic 
research done at the University of Cambridge. The technology addresses some of 
the key challenges in drug discovery R&D by integrating molecular design with 
chemical synthesis. PostEra partners with drug hunters to help expedite their 
preclinical programs while also offering some of its synthesis technology via 
its Manifold ( 
) web platform. PostEra also launched and now helps lead the world's largest 
open-science drug discovery effort; COVID Moonshot. 


CONTACT: Aaron Morris,